ThromboGenics Presents Positive Pooled Results from the MIVI-TRUST Phase III Program

07-Sep-2010 - ThromboGenics NV announced that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented at the EURETINA (European Society of Retina Specialists) Congress in Paris, France. The MIVI-TRUST program is the largest interventional clinical program ever performed ...

Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial

02-Sep-2010 - ThromboGenics NV announced that its second Phase III trial evaluating microplasmin for the non-surgical treatment of vitreomacular adhesion (VMA) has met its primary endpoint. Importantly, the trial also confirmed the positive results seen in the first Phase III trial with microplasmin. The ...

ThromboGenics Announces Publication of Positive Microplasmin Phase II Data

19-Jul-2010 - ThromboGenics NV announces that positive microplasmin Phase II trial results, evaluating the product for the nonsurgical treatment of vitreomacular adhesion, have been published in the journal Retina. The paper is entitled “Intravitreal Injection of Microplasmin for Treatment of Vitreomacular ...

ThromboGenics Announces that Microplasmin Meets Primary Endpoint in Phase III Trial for Vitreomacular Adhesion

Highly significant trial result (p=0.003) demonstrates the potential of microplasmin in the treatment of retinal disease

21-Apr-2010 - ThromboGenics NV announced that its first Phase III trial with microplasmin for the non-surgical treatment of eye disease has met its primary endpoint (p=0.003). The trial, TG-MV-006, recruited a total of 326 patients in the U.S. A second Phase III study with microplasmin, TG-MV-007, which ...

ThromboGenics Completes Patient Enrolment of Phase III Trial of Microplasmin for the Non-Surgical Treatment of Eye Disease

MIVI-TRUST Phase III Program With Microplasmin Recruits a Total of Over 640 patients Ahead of Schedule

21-Dec-2009 - ThromboGenics NV announced that it has completed the enrolment of the second Phase III trial evaluating microplasmin for the non-surgical treatment of eye disease. The trial TG-MV-007, which recruited patients both inEuropeandthe United States, has completed enrolment of over 320 patients across ...

ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-related Macular Degeneration (AMD)

11-Dec-2009 - ThromboGenics NV announced that it has started a Phase II trial of microplasmin for the treatment of exudative (wet) Age-related Macular Degeneration (AMD). Abnormalities in the vitreomacular interface (the interface of the vitreous and macula) have been implicated in wet AMD, and recent ...

ThromboGenics Announces Results From a Phase IIa Trial Evaluating Microplasmin for the Treatment of Diabetic Macular Edema

06-Oct-2009 - ThromboGenics NV announced results of a Phase IIa trial evaluating microplasmin intravitreal injection for the treatment of Diabetic Macular Edema (MIVI II DME). The data from this trial were presented at the ASRS (American Society of Retina Specialists) Conference in New York by Professor Peter ...

ThromboGenics Begins Phase III Program with Microplasmin for the Non-surgical Treatment of Back of the Eye Disease

ThromboGenics’ lead product to be studied in the treatment of vitreomacular adhesion in the US and Europe

12-Jan-2009 - ThromboGenics NV announced that it has started the Phase III clinical program of microplasmin for the non-surgical treatment of back of the eye disease, the final step in the clinical development of this potential new therapy. This program involves two clinical trials, taking place in the United ...

ThromboGenics Announces Promising Six Month Follow-Up Results from its Phase IIb Trial of Microplasmin (MIVI III)

Results continue to support microplasmin’s potential to make a major contribution to the treatment of back of the eye disease

17-Nov-2008 - ThromboGenics NV announced promising six month follow-up results from its Phase IIb MIVI III trial, which was designed to evaluate the safety and efficacy of microplasmin in vitrectomy. The results were presented at the American Academy of Ophthalmology in Atlanta, USA, by Dr. Kirk Packo, ...

ThromboGenics Presents Further Results of the Vitreomacular Traction Trial (MIVI IIT)

Results confirm the beneficial effects of microplasmin in patients with vitreomacular traction without need for vitrectomy throughout the 6 month follow-up period

27-May-2008 - ThromboGenics NV presented the six month follow up results from its Phase IIa MIVI IIT trial at the Euretina Congress in Vienna, Austria. The trial, which delivered positive clinical results in a number of the treated patients, was designed to evaluate both the safety and efficacy of microplasmin ...